Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Upcoming events – catalysts approach for Catalyst and Oxurion
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Novartis sees hidden value in Xiidra
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Lukewarm data for Second Sight
Second Sight’s second product might lead the company to second place in the market.
Aldeyra seeks to Alleviate worries with conjunctivitis win
Pivotal data validate Aldeyra’s lead project, reproxalap, but there are questions about a lack of dose response.
Upcoming events – Roche aims to change autism and Ocular awaits pivotal results
Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
Nightstar gives Biogen a cheap way to expand in gene therapy
Biogen’s $877m buyout of Nightstar Therapeutics provides yet more evidence that gene therapy is reaching critical mass.
Reneuron eyes a partner with new stem cell data
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.